Cyclooxygenase
Research reports from Ohio State University provide new insights into cyclooxygenase
Published in Vaccine Weekly, August 26th, 2009
According to recent research from the United States, "Francisella tularensis, a bacterium which causes tularemia in humans, is classified as a CDC category A bioterrorism agent. In this study, we demonstrate that celecoxib, an anti-inflammatory cyclooxygenase-2 inhibitor in clinical use, exhibits activity against a type A strain of F. tularensis (Schu S4), the live vaccine strain of F. tularensis (a type B strain), and F. novicida (''F. tularensis subsp. novicida'') directly in growth medium."
"This bacterial killing, however, was not noted with rofecoxib, despite its higher potency than that of celecoxib in inhibiting cyclooxygenase-2. The unique ability of celecoxib...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-08-26)
More Articles from Vaccine Weekly
- Wiley-Blackwell
Studies reveal hepatitis C virus carriers experience substantial increase in mortality - Chagas Disease
Data on Chagas disease described by researchers at University of Alabama - Ebola Hemorrhagic Fever
Investigators at Boston University, Medical Department have published new data on ebola hemorrhagic fever - Epstein-Barr Virus
Research from Rockefeller University broadens understanding of Epstein-Barr virus - Fibrosarcoma
Studies from T. Weiss et al have provided new data on fibrosarcoma - Flu Vaccines
NanoPass Makes its MicronJet Technology Available to Increase Global Supply of Pandemic Influenza Vaccines - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
